Description
Cordiamin (Nikethamide) 250 mg/ml Ampoules 2 ml №10
Composition
Active Ingredient: Nikethamide 250 mg/ml
Mechanism of Action
Nikethamide acts as a respiratory stimulant and vasodilator. It improves oxygenation and tissue perfusion by increasing blood flow and oxygen delivery to tissues.
Pharmacological Properties
Cordiamin, containing Nikethamide, exhibits properties that aid in enhancing respiratory function and improving outcomes in circulatory and respiratory failure, shock conditions, and neonatal asphyxia.
Indications for Use
Cordiamin is indicated for the treatment of acute circulatory and respiratory failure, shock conditions, and neonatal asphyxia.
Contraindications
Do not use Cordiamin in patients with hypersensitivity to Nikethamide or in cases of severe hypertension.
Side Effects
Common side effects may include nausea, vomiting, headache, and allergic reactions. Monitor closely for any adverse reactions.
Usage Instructions
Dosage: The usual dose is 1-2 ampoules (2-4 ml) injected intramuscularly or intravenously. Dosage should be individualized based on patient needs and as directed by a healthcare professional.
Benefits Compared to Analogues
Cordiamin has been shown to be effective in improving oxygenation, tissue perfusion, and overall outcomes in circulatory and respiratory failure compared to other similar medications.
Suitable Patient Groups
Cordiamin is suitable for use in both adult and pediatric populations, including neonates, under appropriate medical supervision.
Storage and Shelf Life
- Storage: Keep at room temperature, protected from moisture and heat.
- Shelf Life: Check the expiration date on the packaging and do not use after the stated date.
Packaging Description
Cordiamin is available in boxes containing 10 ampoules, each with a concentration of Nikethamide 250 mg/ml in a 2 ml solution.
Clinical Evidence and Proven Effectiveness
Clinical studies have shown that Cordiamin (Nikethamide) 250 mg/ml ampoules are effective in improving oxygenation and tissue perfusion in patients with circulatory and respiratory failure. Nikethamide has demonstrated positive outcomes in shock states and neonatal asphyxia, with research indicating enhanced respiratory function and reduced hypoxia severity in neonates.
